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A Recurrent Translocation, t(3;11)(q21;q13), Found in 
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Juli rt Marin, Enrique Bengoechea, and Arturo Gull6n 
ABSTRACT:  We report wo cases of acute myeloid leukemia (M1 and M5B subtypes) with a similar trans- 
location, t(3;11)(q21;q13). We discuss the involvement of these breakpoints in acute leukemia and their 
putative clinical implications. 
INTRODUCrION 
Karyotypes with single chromosomal rearrangements involv- 
ing band q13 of chromosome 11 are a quite rare finding in 
acute myeloid leukemia (AML) and are associated with cases 
of M4 and M5 FAB subtypes [1, 2]. Rearrangements of the 
long arm of chromosome 3 affecting bands q21-q26 have been 
reported both in cases associated with an abnormal throm- 
bopoiesis [3-5] and in cases lacking such an association [6, 
7]. The joining of both events, that is, rearrangements involv- 
ing breakpoints 3q26 and 11q13, has been recently described 
in a case of M4 AML [2]. We report two cases of AML with 
a reciprocal translocation between chromosomes 3 and 11 
with breakpoints at bands q21 and q13, respectively. 
PATIENTS AND METHODS 
Pat ient 1 
A 58-year-old woman was admitted to the hospital in Au- 
gust 1993 because of asthenia nd anorexia during the last 
month. Physical examination revealed pallor and gingival 
hypertrophy. Blood findings were 17.8 × 109/L white blood 
cell (WBC) count (56% of atypical monocytes and 2% blasts), 
hemoglobin 10.1 g/dL, and platelet count 67 x 109/L. After 
morphologic examination of bone marrow aspirate, a diag- 
nosis of acute nonlymphocytic leukemia of the FAB subtype 
M5 B was made. Immunologic markers were as follows: CD45 
(100%), CD14 (40%), HLA-DR (90%), CD13 (67%), CD33 
(91%), CD56 (53%), and CD16 (16%). A complete remission 
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was induced after 3 x 7 cycles of treatment with daunoblastin 
and cytarabine, and the patient now remains asymptomatic. 
Pat ient 2 
A 22-year-old man was admitted to the hospital in Novem- 
ber 1993 because of pallor. Blood cell counts were 3.4 x 
109/L WBC count  (40O/o of blasts), hemoglobin 7.4 g/dL, and 
platelet count 58 x 109/L. After morphologic examination 
of bone marrow aspirate, a diagnosis of acute nonlympho- 
cytic leukemia of the FAB subtype M1 was made. Peroxidase 
was positive for 38% of blasts, PAS and naftol-acetate-esterase 
tests were concordant with this diagnosis. A complete remis- 
sion was induced after 3 x 7 cycles of treatment with doxy- 
rubicine and cytarabine, and the patient now remains asymp- 
tomatic. 
Bone marrow cells were short-term cultured (24-48 hours) 
and analyzed by standard cytogenetic methods which include 
Trypsin-Giemsa banding. Samples from both patients were 
examined at diagnosis, during treatment, and at hematologic 
remission. 
RESULTS 
Patient 1 at diagnosis showed the following karyotype: 
46,XX,t(3;11)(q21;q13) in all 30 observed metaphases. Dur- 
ing the treatment we performed a new analysis and we ob- 
served 20 metaphases with normal karyotype and 15 meta- 
phases with the same t(3;11) translocation. Once hematologic 
remission was achieved, anew sample was analyzed and we 
saw only normal cells, confirming the remission also at the 
cytogenetic level. 
Patient 2 had a similar cytogenetic story. At diagnosis, 10 
cells showed a normal karyotype and 15 cells showed the 
following karyotype: 46,XY, t(3;11)(q21;q13). During the treat- 
ment the proportion of normal cells increased (20 normal 
cells, 10 cells with the translocation), and finally, when 
hematologic remission was induced only normal cells were 
seen. Partial karyotypes of both cases are shown in Figure 1. 
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Figure 1 Partial karyotype of patients I (A) and 2 (B) with a simi- 
lar t(3;11)(q21;q13) translocation. Arrowheads how the involved 
breakpoints. 
DISCUSSION 
From the cytogenetic point of view, two aspects are of in- 
terest in this report. Firstly the fact that in both cases, de- 
spite the presence of rearrangements of band 3q21, abnor- 
mal megakaryopoiesis was not demonstrable. Thus, the 
proposed association between breakpoints at 3q21 and 3q26 
and that feature [3-5] might be restricted either to the distal 
breakpoint or to the simultaneous involvements ofboth chro- 
mosomal segments. We agree with the suggestion of Kwong 
et al. (1993) about this relationship: rearrangements of 3q26 
(3q21 in our case) may play an important role in leukemo- 
genesis and may or may not affect different candidate genes, 
with one (some) associated with abnormal thrombopoiesis. 
On the other hand, the involvement of band 11q13 is not a 
common finding in AML, however, its recurrence in M4 and 
M5 FAB subtypes hould be considered for the future. The 
molecular references for this segment tell us nothing about 
the role in leukemogenesis in the two genes so far mapped 
within it [8, 9]. These genes (named BCL-1 and PRAD1) are 
clearly involved in lymphomagenesis but nothing is known 
about their importance in AML. 
Our patients were classified as having M5 B (Patient 1) 
and M1 (Patient 2) AML. Thus the translocation does not 
seem to be very specific for a determinate subtype of AML. 
However, taking together all the reported cases with single 
chromosomal rearrangements of 11q13, including one of our 
cases, it is relevant that they correspond to either the M4 or 
the M5 subtype [1, 2]. If there is a new subset of AML as- 
sociated with this type of rearrangement it is still not clear, 
but waits yet to be determined. 
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